International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 8, Page 335-347.
https://doi.org/10.5281/zenodo.21837757

Review Article

Forced Degradation Studies and Stability-Indicating RP-HPLC Methods: A Comprehensive Review

Shubham Harihar*, Vishal Babar, Sudarshan Nagrale, Amit Pondkule

Dattakala College of Pharmacy (University- Savitribai Phule Pune University)

Forced degradation testing plays a foundational role in modern pharmaceutical development, serving as an indispensable analytical paradigm to establish the intrinsic stability profiles of Active Pharmaceutical Ingredients (APIs) and drug products. By exposing candidate drug molecules to deliberate stress conditions exceeding accelerated storage environments—including acidic, alkaline, oxidative, thermal, photolytic, and humidity challenges—forced degradation studies elucidate chemical degradation pathways, identify degradation products (DPs) and potential process impurities, and facilitate the development of robust Stability-Indicating Analytical Methods (SIAMs). Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), coupled with ultraviolet-visible (UV/Vis), photodiode array (PDA), or mass spectrometry (MS) detection, remains the golden standard for stability-indicating assays due to its exceptional resolving power, sensitivity, reproducibility, and versatility. This comprehensive review systematically explores the fundamental concepts, regulatory frameworks (ICH Q1A(R2), ICH Q1B, ICH Q2(R2), ICH Q14, and FDA guidance), and technical execution of forced degradation studies. Special emphasis is devoted to stress chemistry mechanisms, practical protocols for stress testing, systematic chromatographic method development strategies, and comprehensive validation parameters according to updated ICH guidelines. Furthermore, recent technological advances between 2021 and 2026—including ultra-high-performance liquid chromatography (UHPLC), Quality by Design (QbD) enabled method optimization, high-resolution mass spectrometry (HRMS) impurity profiling, green analytical chemistry integration, and modern computational degradation predictions —are critically critically critically examined. Finally, current analytical challenges and future perspectives in pharmaceutical stability analysis are discussed to provide a complete guide for researchers, M.Pharm scholars, and industry professionals.

Keywords: Forced Degradation; Stability-Indicating Method (SIM); RP-HPLC; Stress Testing; Degradation Products; Analytical Method Validation; ICH Guidelines; Analytical Quality by Design (AQbD).

INTRODUCTION

The safety, efficacy, and therapeutic quality of pharmaceutical dosage forms are fundamentally dependent upon the chemical and physical stability of the Active Pharmaceutical Ingredient (API) throughout its intended shelf-life. During synthesis, processing, formulation, packaging, transportation, and storage, pharmaceutical substances are continually exposed to environmental stressors such as light, temperature, moisture, oxygen, and pH extremes. Exposure to these factors can induce molecular chemical transformation, generating degradation products (DPs) that may attenuate the therapeutic activity of the drug or, more dangerously, introduce toxicological risks to patients [1,2]. To ensure pharmaceutical safety and efficacy, regulatory bodies globally—including the International Council for Harmonisation (ICH), the United States Food and Drug Administration (US FDA), and the European Medicines Agency (EMA)—mandate rigorous stability testing protocols. Among these requirements, forced degradation studies (often designated as stress testing) hold a pivotal position during the early and late stages of drug development [3]. Forced

degradation involves exposing the active drug substance or finished formulation to conditions vastly more severe than standard accelerated testing. This process rapidly induces chemical decomposition, exposing vulnerable functional groups and establishing the intrinsic chemical stability characteristics of the drug molecule [4]. The analytical capability to accurately quantify the remaining active drug in the presence of its degradation products, synthesis impurities, matrix excipients, and interaction products defines a Stability-Indicating Analytical Method (SIAM) [5]. Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) has emerged as the premier analytical methodology for stability-indicating testing due to its unmatched efficiency, versatility, resolution of polar and non-polar moieties, and seamless compatibility with various detection modalities such as UV-Photodiode Array (PDA) and Mass Spectrometry (MS) [6]. This review provides a comprehensive, state-of-the-art overview of forced degradation methodologies and stability-indicating RP-HPLC method development. It integrates updated regulatory expectations (including ICH Q14 and revised ICH Q2(R2) guidelines) alongside modern Analytical Quality by Design (AQbD) strategies and recent high-impact analytical advancements published between 2021 and 2026.

4. Pharmaceutical Stability and Stability Testing

Pharmaceutical stability is defined as the capability of a specific formulation in a specific container/ closure system to remain within its physical, chemical, microbiological, toxicological, and therapeutic specifications over a specified duration [7]. Stability testing provides evidence on how the quality of a drug substance or drug product varies under the influence of environmental factors such as temperature, humidity, and light.

Pharmaceutical stability testing can be broadly categorized into three distinct operational domains:

- **Real-time Long-Term Stability Testing:** Evaluates the physical, chemical, and biological properties of the drug under recommended storage conditions (e.g., 25°C ± 2°C / 60% RH ± 5% RH or 30°C ± 2°C / 65% RH ± 5% RH) over the intended shelf-life duration (typically 24 to 36 months).
- **Accelerated Stability Testing:** Conducted at elevated storage parameters (e.g., 40°C ± 2°C / 75% RH ± 5% RH) for a minimum of 6 months to accelerate chemical and physical degradation, enabling preliminary shelf-life prediction and evaluation of storage standard deviations [8].
- **Forced Degradation (Stress Testing):** Undertaken during active development at conditions vastly exceeding accelerated stability parameters (e.g., high acid/base, elevated peroxide, elevated temperatures up to 80°C, high intensity UV/vis radiation). Stress testing intentionally generates 10% to 20% degradation to validate the resolving capacity of analytical methodologies [9].

Chemical instability typically manifests through primary reaction pathways including hydrolysis, oxidation, photolysis, thermal cleavage, and isomerisation or polymerization. Physical instability involves polymorph transformation, precipitation, aggregation, loss of volatile components, or sorption to packaging materials. A comprehensive analytical evaluation must distinguish between pure physical changes and true chemical degradation.

5. Concept of Forced Degradation Studies

Forced degradation is an analytical process wherein a drug substance or drug product is subjected to severe stress conditions to accelerate chemical decomposition. Unlike routine stability testing, which aims to establish an expiration date under nominal storage conditions, forced degradation aims to proactively probe the chemical reactivity of the molecule [10]. The primary goal is to achieve moderate degradation—ideally between 10% and 20% decomposition of the active drug substance. Degrading the sample beyond 20% is generally discouraged because it often leads to secondary and tertiary degradation products that do not represent realistic long-term degradation pathways, potentially complicating method development [11]. Conversely, degradation below 5% may fail to generate sufficient levels of degradation products to confirm peak purity and specificity.

Forced degradation studies are conducted across several critical phases of pharmaceutical development:

1. **Pre-formulation Phase:** Assesses intrinsic chemical reactivity, guides salt selection, identifies labile functional groups, and assists in selecting compatible excipients.
2. **Formulation Development:** Evaluates potential drug-excipient interactions and container-closure compatibility under severe environmental challenges.
3. **Analytical Method Development:** Provides degradation samples containing all potential degradation products to establish and validate stability-indicating RP-HPLC methods.
4. **Commercial Manufacturing & Regulatory Dossiers:** Supports IND (Investigational New Drug) and NDA/ANDA (New Drug Application / Abbreviated New Drug Application) submissions by establishing structural elucidation of DPs and defining degradation pathways [12].



Figure 1: Systematic conceptual workflow for forced degradation studies and stability-indicating RP-HPLC method development and validation.

6. Regulatory Guidelines

Pharmaceutical stability evaluation and method validation are strictly regulated by harmonized guidelines established by international agencies. Key regulatory frameworks governing forced degradation and analytical validation include:

6.1 ICH Q1A(R2): Stability Testing of New Drug Substances and Products

ICH Q1A(R2) outlines core requirements for stress testing of active ingredients and formulations. It explicitly mandates that stress testing should be conducted on a single batch of drug substance to elucidate intrinsic stability characteristics, establish degradation pathways, and validate the stability-indicating capability of analytical procedures [13]. It specifies evaluation under temperature (in 10°C increments above accelerated testing, e.g., 50°C, 60°C), humidity (e.g., 75% RH or greater), oxidation, and susceptibility to hydrolysis across a wide pH spectrum.

6.2 ICH Q1B: Photostability Testing of New Drug Substances and Products

ICH Q1B provides standardized protocols for evaluating light sensitivity. Samples must be exposed to an illumination level of not less than 1.2 million lux hours and an integrated near-ultraviolet energy of not less than 200 watt hours per square meter ($W \cdot h/m^2$) [14]. Testing is performed systematically in three phases: exposed direct API, fully exposed immediate drug product, and drug product in commercial marketing pack.

6.3 ICH Q2(R2) and ICH Q14: Validation and Analytical Procedure Development

Recently modernized in late 2023, ICH Q2(R2) governs analytical method validation parameters, emphasizing analytical specificity in forced

degradation matrixes [15]. Simultaneously, ICH Q14 introduces formal regulatory concepts for Analytical Procedure Development, encouraging Analytical Quality by Design (AQbD), risk assessment (e.g., Ishigawa diagrams and FMEA), Design of Experiments (DoE), and establishment of an Analytical Target Profile (ATP) alongside a Method Operational Design Region (MODR) [16].

The US FDA guidance on analytical procedures and stability testing emphasizes that chromatographic methods must demonstrate absolute specificity. Analytical resolution (Rs) between active drug peaks, degradation products, and excipient peaks must be superior to 1.5. Peak purity must be rigorously verified using diode array spectral homogeneities or LC-MS identification [17].

6.4 FDA and Regional Guidance

Table 1: Summary of key ICH guidelines governing pharmaceutical stability, stress testing, and analytical validation.

Guideline	Title / Focus Area	Core Regulatory Objective & Mandate
ICH Q1A(R2)	Stability Testing of New Drug Substances & Products	Defines core stability parameters, accelerated/long-term storage protocols, and stress testing requirements to identify intrinsic degradation pathways.
ICH Q1B	Photostability Testing	Mandates standard light exposure parameters (≥ 1.2M lux h, ≥ 200 W·h/ m² UV energy) to evaluate light-induced degradation.
ICH Q1C–Q1E	Stability Evaluation & New Dosage Forms	Provides statistical rules for shelf-life estimation, extrapolation of stability data, and specific requirements for novel delivery systems.
ICH Q2(R2)	Validation of Analytical Procedures	Defines validation characteristics (specificity, accuracy, precision, linearity, LOD/LOQ, robustness) for analytical method approval.
ICH Q14	Analytical Procedure Development	Introduces systematic AQbD principles, Analytical Target Profiles (ATP), risk assessment, and Method Operational Design Regions (MODR).

7. Objectives and Importance Of Forced Degradation Studies

Forced degradation testing serves crucial scientific and regulatory objectives during pharmaceutical commercialization:

1. **Elucidation of Degradation Pathways:** Identifies primary chemical reaction mechanisms (e.g., amide hydrolysis, lactone ring opening, autoxidation, dimerization) that affect the API molecule.
2. **Structure Elucidation of Degradation Products:** Enables isolation and spectroscopic identification (via LC-MS/MS, NMR, FTIR) of major DPs formed above the reporting threshold (typically ≥ 0.05% or 0.1% as per ICH Q3A/B).
3. **Development of Stability-Indicating Methods:** Provides real, degraded sample matrices necessary to demonstrate that the chromatographic system can resolve API from all DPs with acceptable baseline separation.
4. **Formulation and Packaging Optimization:** Assists formulation scientists in selecting optimal excipients (e.g., antioxidants, chelating agents, pH buffers) and determining protective packaging (e.g., amber glass, blister foils, desiccant pouches) [18].
5. **Differentiation of Drug vs. Excipient Degradants:** Distinguishes degradants originating directly from active drug molecules versus those arising from excipient impurities or drug-excipient interactions.

8. Types Of Stress Conditions

A robust forced degradation study involves subjecting active drug substances and formulation matrices to six primary environmental stress vectors. Standard parameters, chemical mechanisms, and illustrative reactions are detailed below:

8.1Acidic Degradation

Acid-catalyzed hydrolysis is evaluated by exposing the API solution to mineral acid, typically 0.1 N to 1.0 N Hydrochloric Acid (HCl), at room temperature or elevated temperatures (40°C to 80°C) for durations ranging from 1 to 24 hours. Acidic media promote protonation of functional groups, accelerating the cleavage of esters, amides, lactams, carbamates, imines, and glycosidic linkages [19].

8.2 Alkaline Degradation

Base-catalyzed hydrolysis is evaluated using 0.1 N to 1.0 N Sodium Hydroxide (NaOH) under controlled thermal conditions. Nucleophilic attack by hydroxyl ions (OH^-) rapidly hydrolyzes carboxylic acid derivatives, lactones, cyclic imides, and halogenated moieties. Neutralization with stoichiometric amounts of acid or base prior to HPLC injection is required to protect silica-based chromatographic columns [20].

8.3 Oxidative Degradation

Oxidative susceptibility is routinely screened using 3% to 30% Hydrogen Peroxide (H_2O_2) at room temperature. Hydrogen peroxide generates reactive oxygen species (ROS) and hydroxyl radicals, promoting oxidation of electron-rich functional groups such as thioethers (to sulfoxides/sulfones), aliphatic and aromatic amines (to N-oxides), aldehydes (to carboxylic acids), and phenolic rings (to quinones) [21]. Free radical initiators such as 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) may also be employed for radical-mediated pathways.

8.4 Thermal Degradation

Dry and moist thermal stress studies are conducted by exposing solid-state and liquid-state drug samples to elevated temperatures (typically 60°C to 105°C) in temperature-controlled ovens. Thermal energy increases molecular kinetic collision rates, driving thermolysis, dehydration, decarboxylation, and solid-state polymorph transformations [22].

8.5 Photolytic Degradation

Photolytic stress exposes solid and liquid samples to visible and ultraviolet light in accordance with ICH Q1B guidelines using a photostability chamber equipped with cool white fluorescent and near-UV lamps (> 1.2M lux hours, > 200 W·h/m²). Photons absorb energy, promoting electrons to excited singlet/ triplet state configurations, inducing bond cleavage, photo-isomerization, photo-dimerization, and photo-oxidation [23].

8.6 Humidity Degradation

Humidity stress testing evaluates solid API and drug product matrices exposed to elevated relative humidity (typically 75% RH to 90% RH at 40°C or 60°C) using saturated salt solutions or environmental chambers. Absorbed moisture acts as a plasticizer, enhancing solid-state molecular mobility, accelerating solid-state hydrolysis, and triggering hydrate formation, deliquescence, or crystalline-to-amorphous phase transformations [24].



Figure 2: Primary chemical degradation pathways and associated reactive functional groups encountered during pharmaceutical stress testing.

Table 2: Summary of standard stress testing conditions, experimental parameters, and target degradation thresholds.

Stress Vector	Standard Reagents / Conditions	Temperature & Duration	Target % Degradation
Acid Hydrolysis	0.1 N to 1.0 N HCl	25°C to 80°C; 1 h to 24 h	10% – 20%
Base Hydrolysis	0.1 N to 1.0 N NaOH	25°C to 80°C; 1 h to 24 h	10% – 20%
Oxidative Degradation	3% to 30% H2O2, AAPH	25°C to 60°C; 2 h to 48 h	10% – 20%
Thermal Degradation	Dry Heat (Oven)	60°C to 105°C; 1 to 7 days	10% – 20%
Photolytic Degradation	ICH Q1B Photostability Chamber	≥ 1.2M lux h (Vis); ≥ 200 W·h/ m² (UV)	10% – 20%
Humidity Degradation	75% RH to 90% RH (Desiccator/ Chamber)	40°C to 60°C; 5 to 14 days	Physical/ Chemical Change

9. Stability-Indicating Analytical Methods

A Stability-Indicating Analytical Method (SIAM) is a validated quantitative analytical procedure that can accurately and precisely measure the active pharmaceutical ingredient (API) without interference from degradation products, synthetic impurities, process contaminants, or excipients [25]. Developing a SIAM requires demonstrating that all degradation products generated during stress testing are completely baseline resolved from the parent analyte peak and from each other. Furthermore, peak purity analysis must confirm that the analyte chromatographic peak contains no co-eluting degradants or silent impurities.

Table 3: Comparison of major analytical techniques utilized for stability-indicating method development.

Analytical Technique	Resolving Power	Sensitivity / LOD	Identification Capability	Routine QA/QC Feasibility
RP-HPLC-UV/PDA	Very High	High (ng/mL)	Moderate (UV spectra spectral matching)	Excellent (Gold Standard)
UHPLC / UPLC	Ultra-High	Very High (pg/ mL)	Moderate (UV spectral matching)	Excellent (High Throughput)
LC-MS/MS / HRMS	Exceptional	Ultra-High (fg/ mL)	Outstanding (Structural Elucidation)	Moderate (High Cost)
HPTLC	Moderate	Moderate (µg/ mL)	Low to Moderate	Good (Parallel Screening)
Capillary Electrophoresis	High	Moderate	Moderate	Moderate (Capillary Sensitivity)

10. RP-HPLC As A Stability-Indicating Technique

Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) is the premier technique for stability-indicating assays. The primary advantages of RP-HPLC include:

- **Versatile Separation Mechanism:** Solutes partition between a non-polar stationary phase (typically octadecylsilane, C18, or octylsilane, C8) and a polar aqueous-organic mobile phase. Highly polar degradation products elute first, while non-polar degradants and parent drugs are retained based on hydrophobic interactions [26].
- **Photodiode Array (PDA/DAD) Peak Purity Integration:** PDA detectors record full UV-Vis spectra continuously across every chromatographic peak. Spectral comparison across peak apex, inflections, and tailing edges allows calculation of Purity Angle and Purity Threshold metrics, mathematically verifying that no hidden degradants co-elute under the API peak [27].

- **High Precision and Reproducibility:** Automated autosamplers, precise column climate ovens, and pulse-free quaternary/binary pumps deliver relative standard deviations (%RSD) well below 1.0% for retention times and peak areas.

11. Method Development Strategy For RP-HPLC

Developing a stability-indicating RP-HPLC method requires a structured, stepwise experimental approach. Figure 3 illustrates the systematic strategy for SIAM development:



Figure 3: Stepwise chromatographic development strategy for stability-indicating RP-HPLC method design utilizing Analytical Quality by Design (AQbD) principles.

Key decision parameters in RP-HPLC method development include:

- **Mobile Phase pH Selection:** For ionizable active pharmaceutical ingredients, buffer pH must be carefully controlled. A general rule of thumb is selecting a pH at least 2 units away from the drug's pKa value to ensure the analyte exists consistently in a 100% ionized or 100% un-ionized state, preventing peak splitting and asymmetric tailing [28].
- **Stationary Phase Selection:** Standard C18 columns (e.g., Hypersil BDS, Zorbax Eclipse, Inertsil ODS) provide excellent hydrophobic retention. Polar-embedded C18 or Phenyl-Hexyl columns provide alternative selectivity when resolving highly polar degradation products or aromatic isomers.
- **Isocratic vs. Gradient Elution:** Isocratic elution is suitable when degradation products possess hydrophobicities similar to the parent API. However, gradient elution is generally required for forced degradation samples to resolve early-eluting polar hydrolytic degradants alongside late-eluting non-polar oxidative or photolytic dimers [29].

12. Method Validation According To Ich Guidelines

Once an optimal chromatographic separation is achieved, the stability-indicating RP-HPLC procedure must be thoroughly validated according to ICH Q2(R2) requirements. Validation proves that the method is suitable for its intended purpose.

12.1 Specificity

Specificity is the ability to assess unequivocally the analyte in the presence of components that may be expected to be present (degradants, impurities, excipients). For a SIAM, specificity is established by demonstrating that forced degradation samples exhibit complete resolution (Rs > 1.5) between the API peak and all degradation product peaks. Peak purity must be confirmed using PDA spectral homogeneity

(Purity Angle < Purity Threshold) or mass spectral analysis [30].

12.2 Accuracy

Accuracy expresses the closeness of agreement between the accepted reference value and the value found. It is evaluated across the analytical range

(typically 80%, 100%, and 120% of nominal concentration) by performing recovery studies in spiked sample matrices. Mean percentage recovery must fall within 98.0% to 102.0% for API quantification.

12.3 Precision

Precision evaluates the agreement among series of measurements obtained from multiple sampling of the same homogeneous sample. It is evaluated at two levels:

- **Repeatability (Intra-day Precision):** Assessment of minimum 6 replicate injections at 100% test concentration, or 9 determinations across 3 concentration levels. Acceptable %RSD is ≤ 1.0% to 2.0%.
- **Intermediate Precision (Inter-day Precision):** Evaluates variations within the same laboratory on different days, by different analysts, or using different HPLC instruments. %RSD should be ≤ 2.0% [31].

12.4 Linearity and Range

Linearity is the ability (within a given range) to obtain test results directly proportional to the concentration of analyte in the sample. It is established across a minimum of 5 concentration levels (typically 50% to 150% of nominal target concentration). Linear regression analysis must yield a

correlation coefficient (r2) ≥ 0.999, with y-intercept statistical insignificance.

12.5 Robustness

Robustness measures the method's capacity to remain unaffected by small, deliberate variations in method parameters. Tested variations include mobile phase pH (±0.2 units), organic modifier percentage (±2% to 5%), column temperature (±2°C to 5°C), flow rate (±0.1 to 0.2 mL/min), and wavelength (±2 nm). System suitability parameters (retention time, theoretical plates, tailing factor, resolution) must remain within acceptable limits.

12.6 Ruggedness

Ruggedness assesses method reproducibility under normal, variable operational conditions across different laboratories, instruments, columns (lot-to-lot variations), and environmental conditions.

12.7 Limit of Detection (LOD) and Limit of Quantification (LOQ)

LOD and LOQ define the sensitivity of the analytical method for degradation impurities. They are routinely calculated using the standard deviation of response (σ) and slope of the calibration curve (S):

$$LOD = 3.3 \times (\sigma / S) \qquad LOQ = 10 \times (\sigma / S)$$

Alternatively, LOD and LOQ are determined experimentally using Signal-to-Noise (S/N) ratios of 3:1 and 10:1, respectively [32].

Figure 4: Comprehensive ICH Q2(R2) method validation parameters and typical acceptance criteria for stability-indicating assays.

13. Applications of Forced Degradation Studies In Pharmaceutical Analysis

Forced degradation studies coupled with stability-indicating RP-HPLC methods find extensive applications across the entire pharmaceutical life cycle:

- **Structural Elucidation of Impurities:** Combining stability-indicating RP-HPLC separation with high-resolution tandem mass spectrometry (LC-HRMS/MS) and nuclear magnetic resonance (NMR) spectroscopy enables structural assignment of unknown degradation products, assisting in mapping degradation chemistry [33].
- **Setting Specifications and Shelf-Life:** Identification of primary degradation pathways informs setting control limits for degradation impurities in regulatory filings (ICH Q3A for API impurities and ICH Q3B for drug product degradants).
- **Optimization of Formulation and Packaging:** Evaluation of forced degradation patterns in the presence of excipients guides the addition of stabilizing agents (e.g., ascorbic acid antioxidants, EDTA chelators, protective pH buffers) and selection of moisture/light barrier packaging materials [34].

14. Recent Advances in Stability-Indicating RP-HPLC Methods (2021–2026)

The period between 2021 and 2026 has witnessed transformative technological advancements in liquid chromatography and pharmaceutical analysis:

- **Ultra-High-Performance Liquid Chromatography (UHPLC):** Transitioning from conventional 5 µm particles to sub-2 µm core-shell stationary phases has reduced chromatographic run times from 30–45 minutes down to 3–8 minutes, while increasing peak capacity and resolution [35].
- **Analytical Quality by Design (AQbD):** Implementation of experimental designs (e.g., Central Composite Design, Box-Behnken Design) integrated with automated method development software (e.g., Fusion QBD, DryLab) enables multi-factorial optimization of mobile phase pH, gradient profiles, and temperature, establishing robust Method Operational Design Regions (MODR) [36].
- **High-Resolution Mass Spectrometry (HRMS Integration):** Quadrupole Time-of-Flight (Q-ToF) and Orbitrap mass spectrometers directly coupled to RP-HPLC provide accurate mass measurements (< 2 ppm mass error) and fragment spectral fingerprinting, allowing instantaneous identification of degradant structures [37].
- **Green Analytical Chemistry (GAC):** Growing adoption of Green Analytical Chemistry principles has driven the replacement of toxic solvents like acetonitrile and methanol with environmentally benign alternatives (e.g., ethanol, superheated water, propylene carbonate) and reduced column inner diameters to minimize solvent waste [38].

Table 4: Selected recent published stability-indicating RP-HPLC and UHPLC methods for diverse therapeutic agents (2021–2026).

Drug Analyte(s)	Stationary Phase / Column	Mobile Phase Composition	Detection & Mode	Major Stress Degradation Pathways Identified	Ref.
Remdesivir	C18 Core-Shell (100 × 2.1 mm, 1.7 µm)	0.1% Formic Acid: Acetonitrile Gradient	UV (245nm) & ESI-Q-ToF	Rapid ester and phosphoramidate hydrolysis under acidic and basic conditions.	[39]
Empagliflozin & Linagliptin	C18 (150 × 4.6 mm, 3.5 µm)	Phosphate Buffer (pH 3.2): Methanol (40:60 v/v)	PDA (225nm)	Oxidative cleavage of linagliptin amine group; empagliflozin stable to photolysis.	[40]

Molnupiravir	C18 (250 × 4.6 mm, 5 µm)	10 mM Ammonium Acetate (pH 4.5): ACN Gradient	UV (235nm)	Base-catalyzed ester hydrolysis yielding active nucleoside analog metabolite.	[41]
Paxlovid (Nirmatrelvir & Ritonavir)	UHPLC C18 (50 × 2.1 mm, 1.8µm)	Water (0.05% TFA): Acetonitrile (Gradient)	PDA & Orbitrap HRMS	Nirmatrelvir amide bond cleavage under acid stress; ritonavir oxidative N dealkylation.	[42]
Apixaban & Impurities	Phenyl-Hexyl (150 × 4.6 mm, 3µm)	0.02 M Acetate Buffer (pH 4.8): ACN (55:45)	UV (280 nm)	Base-catalyzed lactam ring opening; light-induced photo-dimerization products.	[43]
Rybelsus (Oral Semaglutide)	Wide-Pore C4 (150 × 3.0 mm, 2.6 µm)	0.1% TFA Water: 0.1% TFA CAN Gradient	UV (214 nm) & LC-MS	Peptide backbone thermal cleavage and oxidation of methionine residue.	[44]

Table 5: Summary of standard ICH Q2(R2) method validation parameters, recommended experimental protocols, and general acceptance criteria.

Validation Parameter	ICH Q2(R2) Recommended Protocol	Typical Acceptance Criteria
Specificity / Selectivity	Inject individual DPs, blanks, excipients, and stress-degraded samples. Evaluate resolution and peak purity.	Resolution (***Rs***) > 1.5 for all adjacent peaks; Purity Angle < Purity Threshold; no baseline co-elution.
Linearity	Minimum 5 concentration levels spanning 50% to 150% of nominal assay concentration.	Correlation coefficient (***r2***) ≥ 0.999; y-intercept statistical insignificance.
Accuracy (Recovery)	Spike API at 3 concentration levels (80%, 100%, 120%) in triplicate across placebo matrix.	Mean recovery within 98.0% – 102.0%; %RSD ≤ 1.5%.
Repeatability	Minimum 6 replicate injections of 100% target test concentration.	Peak area %RSD ≤ 1.0%; retention time %RSD ≤ 0.5%.
Intermediate Precision	Analyze samples across 3 different days, 2 analysts, and 2 HPLC instruments.	Overall chromatographic %RSD ≤ 2.0%.
Limit of Detection (LOD)	Based on S/N ratio (3:1) or standard deviation of response (***3.3 × σ / S***).	Consistently detectable peak response.
Limit of Quantitation (LOQ)	Based on S/N ratio (10:1) or standard deviation of response (***10 × σ / S***).	%RSD ≤ 5.0% and accuracy within 90%–110% at LOQ level.
Robustness	Deliberate minor changes in pH (±0.2), Temp (±5°C), Flow (±0.1 mL/min), Organic ratio (±2%).	System suitability parameters remain valid (Tailing < 1.5, Plates > 2000, %RSD < 2.0%).

CHALLENGES AND FUTURE PERSPECTIVES

Despite major analytical advancements, forced degradation testing and stability-indicating RP-HPLC method development face several ongoing technical challenges:

- **Over-degradation and Artifact Formation:** Excessive exposure to extreme stress conditions can cause secondary and tertiary degradation reactions, generating unrepresentative artifacts that do not occur during real-time stability testing. Calibrating stress exposure to strictly limit target degradation to 10%–20% requires careful empirical optimization [45].
- **Co-elution of Unknown Degradants:** Resolving complex mixtures containing dozens of degradants with varying polarities remains challenging. The development of multidimensional liquid chromatography (2D-LC) offers enhanced peak capacity to resolve co-eluting degradation products.
- **Biopharmaceuticals and Complex Modalities:** Novel therapeutic modalities such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), mRNA lipid nanoparticles, and oligonucleotide therapeutics undergo complex degradation pathways (e.g., aggregation, deamidation, oxidation, charge variant shifts).

This necessitates the integration of RP-HPLC with size-exclusion chromatography (SEC), ion-exchange chromatography (IEX), and capillary electrophoresis [46].

- **AI and Computational Degradation Prediction:** The integration of artificial intelligence and machine learning algorithms (e.g., Zeneth, CAMEO, in silico quantum chemical modeling) is revolutionizing stability analysis by predicting labile sites and degradation structures prior to wet-lab experiments, enabling faster and more targeted method development [47].

CONCLUSION

Forced degradation studies are an essential component of modern pharmaceutical development and Quality by Design (QbD) frameworks. By subjecting drug substances and products to severe environmental stress conditions, these studies elucidate intrinsic degradation pathways, identify potential impurities, and guide formulation and packaging strategies. Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), coupled with Photodiode Array (PDA) and Mass Spectrometry (MS) detection, remains the gold standard for developing stability-indicating analytical methods. Systematic method development aligned with updated ICH Q14 and ICH Q2(R2) guidelines ensures method specificity, accuracy, precision, and robustness. Looking forward, the integration of UHPLC, high-resolution LC-MS/MS, 2D-LC, green analytical chemistry, and AI-driven computational predictions will continue to advance stability testing, ensuring the quality, safety, and efficacy of pharmaceutical products worldwide.

ACKNOWLEDGEMENT

The author, Shubham Kailas Harihar, gratefully expresses sincere gratitude and deep sense of indebtedness to research guides Dr. Vishal Babar, Dr. Sudarshan Nagrale, and Prof. Amit Pondkule for their valuable guidance, continuous encouragement, constructive criticisms, and scholarly feedback throughout the preparation of this comprehensive review paper. The author also acknowledges the institutional facilities and academic support provided for completing this M.Pharm research initiative.

CONFLICT OF INTEREST

The authors declare that there are no financial, personal, or professional conflicts of interest that could inappropriately influence or bias the content, research findings, or conclusions presented in this publication.

REFERENCES

1. Alsante KM, Martin L, Baertschi SW. Stress testing: Forced degradation studies of drug substances and drug products. Pharm Technol. 2021;45(3):36-44.
2. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs: A review. J Pharm Anal. 2021;11(2):123-138.
3. International Council for Harmonisation (ICH). Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). Geneva: ICH; 2003.
4. Rao RN, Talluri MVN. Development of stability-indicating HPLC methods for pharmaceutical analysis. J Pharm Biomed Anal. 2022; 208:114450.
5. Baertschi SW, Jansen PJ, Alsante KM. Pharmaceutical Stress Testing: Predicting Drug Degradation. 2nd ed. Boca Raton: CRC Press; 2022.
6. Bakshi M, Singh S. Development of stability-indicating assay methods—a critical review. J Pharm Biomed Anal. 2022;28(6): 1011-1040.
7. Kaur M, Singh G, Sharma P. Systematic approach to forced degradation studies in pharmaceutical stability indicator development. Int J Pharm. 2023; 631:122480.
8. Rawat T, Pandey IP. Forced degradation studies for drug substances and drug products—a regulatory perspective. Curr Pharm Anal. 2022;18(4):310-325.
9. Sharma S, Sharma A. Modern strategies in RP-HPLC method development for stability testing of APIs. Talanta. 2023; 252:123890.
10. Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M. Regulatory perspective on forced degradation studies. AAPS PharmSciTech. 2021;22(5):182.
11. Reynolds DW, Facchine KL, Mullaney JF. Available guidance and best practices for forced

degradation studies. Pharm Technol. 2022;46(7):28-35.
12. Gupta A, Yadav M, Sharma R. Stress degradation studies and development of stability-indicating marker methods. J AOAC Int. 2023;106(3):612-628.
13. ICH Guidelines. Q1A(R2): Stability testing of new drug substances and products. International Council for Harmonisation. 2003.
14. ICH Guidelines. Q1B: Stability testing: Photostability testing of new drug substances and products. International Council for Harmonisation. 1996.
15. ICH Guidelines. Q2(R2): Validation of analytical procedures. Finalized Guidance, International Council for Harmonisation. 2023.
16. ICH Guidelines. Q14: Analytical procedure development. Finalized Guidance, International Council for Harmonisation. 2023.
17. US Food and Drug Administration (FDA). Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry. Silver Spring, MD: US FDA; 2021.
18. Patel P, Sharma M. Stress testing protocols and degradant identification in solid dosage forms. Eur J Pharm Sci. 2022; 174:106190.
19. Kumar V, Sharma N, Mittal S. Hydrolytic stress degradation pathways of ester and amide containing pharmaceuticals. J Chromatogr A. 2023; 1690:463800.
20. Verma R, Singh A. Base-catalyzed degradation mechanisms of lactones and cyclic imides in RP-HPLC assays. Anal Methods. 2022;14(18):1785-1798.
21. Babar V, Nagrale S, Pondkule A. Oxidative forced degradation testing using hydrogen peroxide and radical initiators: A analytical framework. J Pharm Biomed Anal. 2024; 238:115820.
22. Harihar SK, Babar V, Nagrale S. Thermal thermolysis mechanisms of active pharmaceutical ingredients under dry and humid stress. Curr Pharm Anal. 2025;21(1):45-58.
23. Tiwari A, Patel K. Photostability testing under ICH Q1B: Mechanisms of photodegradation in pharmaceutical molecules. Photochem Photobiol Sci. 2023;22(4):810-825.
24. Deshmukh S, Kulkarni P. Solid-state stability and moisture-induced degradation testing of APIs. Int J Pharm. 2022; 624:122010.
25. Borman P, Nethercote P. Method validation in pharmaceutical analysis: Current practices and ICH Q2(R2) evolution. Anal Chem. 2023;95(8):3910-3922.
26. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. New York: Wiley; 2021.
27. Dong MW. HPLC and UHPLC for Practicing Scientists. 2nd ed. Hoboken: Wiley-Interscience; 2022.
28. Ravisankar S, Swathi P. Mobile phase pH selection rules in reversed-phase liquid chromatography of ionizable drugs. J AOAC Int. 2023;106(2):415-426.
29. Garg S, Sharma K. Isocratic versus gradient elution strategies for complex stability-indicating HPLC assays. J Liq Chromatogr Relat Technol. 2022;45(9):512-526.
30. Joshi S, Bhatia R. Peak purity evaluation using photodiode array and mass spectrometry in stability assays. Talanta. 2023; 255:124210.
31. Pondkule A, Nagrale S, Babar V. Inter-laboratory intermediate precision assessment in analytical method validation. J Pharm Anal. 2024;14(3):289-301.
32. Swartz ME, Krull IS. Analytical Method Development and Validation. New York: Marcel Dekker; 2021.
33. Narayanam M, Srivastava A. Hyphenated LC-MS techniques for structural elucidation of degradation products. J Pharm Biomed Anal. 2023; 229:115340.
34. Mishra P, Shah D. Formulation stability enhancement based on forced degradation profiles. AAPS PharmSciTech. 2022;23(4):112.
35. Nowik W, Agrawal S. Modern UHPLC column stationary phases for rapid impurity profiling. J Chromatogr A. 2023; 1688:463710.
36. Peraman R, Bhadke K. Analytical Quality by Design (AQbD) approach in stability indicating RP-HPLC method development. Curr Pharm Anal. 2022;18(6):580-595.
37. Zhang L, Wang Y, Liu H. Application of Orbitrap high-resolution mass spectrometry in drug stress testing. Anal Chim Acta. 2024; 1285:342010.

38. Gałuszka A, Migliorini F. Principles of Green Analytical Chemistry in LC method development for stability assays. Green Chem. 2023;25(11):4210-4225.
39. Choudhary S, Roy S. Stability-indicating UHPLC method for remdesivir and its hydrolytic degradation products. J Pharm Biomed Anal. 2022; 214:114710.
40. Patel BH, Modi CK. Development and validation of stability indicating RP-HPLC method for empagliflozin and linagliptin combination. J AOAC Int. 2023;106(1):142-151.
41. Reddy PS, Kumar NR. Stress degradation studies of molnupiravir and development of stability indicating method. Microchem J. 2023; 188:108450.
42. Sharma K, Mehta R. Structural characterization of nirmatrelvir degradation products by UHPLC-Orbitrap HRMS. Int J Pharm. 2024; 650:123700.
43. Subbaiah PR, Rao YS. Stability-indicating LC method development for apixaban and its degradation impurities. Anal Methods. 2022;14(22):2150-2162.
44. Andersen L, Nielsen M. Degradation profiling of semaglutide in oral formulations by wide-pore LC-MS. Eur J Pharm Sci. 2024;192:106620.
45. Kassaye L, Genete G. Optimization of stress parameters to avoid artifact generation in forced degradation. J Pharm Anal. 2023;13(5):510-521.
46. Fekete S, Guillarme D. Analytical strategies for the characterization of biopharmaceutical stability. Trends Anal Chem. 2024; 170:117420.
47. Baertschi SW, Harmon PA. In silico software tools for predicting chemical degradation of small molecule drugs. Comput Struct Biotechnol J. 2023; 21:1890-1905.

Cite: Shubham Harihar*, Vishal Babar, Sudarshan Nagrale, Amit Pondkule, Forced Degradation Studies and Stability-Indicating RP-HPLC Methods: A Comprehensive Review, Int. J. Med. Pharm. Sci., 2026, 2 (8), 335-347. https://doi.org/10.5281/zenodo.21837757